Arctic Bioscience

Privately held: no public share price

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
Lipid pathway (herring roe extract)Small molecule
Psoriasis

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

14 October 2024Topline resultHRO350HeROPA Phase 2b (NCT06125808) 6-month topline: primary endpoint (PASI50) not met
Arctic Bioscience · Source ↗

Financial reports

No financial reports recorded.